Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global population that can lead to end-stage liver disease and hepatocellular carcinoma (HCC). NAFLD is closely linked to the metabolic syndrome, and comorbidities such as type 2 diabetes, obesity and insulin resistance aggravate liver disease, while NAFLD promotes cardiovascular risk in affected patients. The pathomechanisms of NAFLD are multifaceted, combining hepatic factors including lipotoxicity, mechanisms of cell death and liver inflammation with extrahepatic factors including metabolic disturbance and dysbiosis. Nuclear receptors (NRs) are a family of ligand-controlled transcription factors that regulate glucose, fat and cholesterol homeostasis and modulate innate immune cell functions, including liver macrophages. In parallel with metabolic derangement in NAFLD, altered NR signaling is frequently observed and might be involved in the pathogenesis. Therapeutically, clinical data indicate that single drug targets thus far have been insufficient for reaching patient-relevant endpoints. Therefore, combinatorial treatment strategies with multiple drug targets or drugs with multiple mechanisms of actions could possibly bring advantages, by providing a more holistic therapeutic approach. In this context, peroxisome proliferator-activated receptors (PPARs) and other NRs are of great interest as they are involved in wide-ranging and multi-organ activities associated with NASH progression or regression. In this review, we summarize recent advances in understanding the pathogenesis of NAFLD, focusing on mechanisms of cell death, immunometabolism and the role of NRs. We outline novel therapeutic strategies and discuss remaining challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metabolic processes in both hepatocytes and non-parenchymal liver cells are modulated by nuclear receptors”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 1×
“MPT-driven necrosis, as a type of regulated cell death, is caused by toxins- or oxidative stress-induced cell microenvironment disturbances, which lead to the sudden disability of mitochondrial membrane potential and subsequent cell membrane rupture [41].”
BackgroundGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased profoundly over the last decades-to date, representing the most common cause of chronic liver disease worldwide and numbers are expected to increase even further [1,2].”
BackgroundObesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 1×
“The accumulation of pro-inflammatory macrophages in lipid-enriched liver has been identified as a cause of obesity-induced chronic inflammation [81].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 2×
“As awareness of NAFLD is increasing globally [206], ongoing preclinical and clinical studies provided various pathomechanistic insights into disease development and progression, identifying many new potential drug targets [24,207,208].”
BackgroundPyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,183 · cited 1×
“Morphologically, the pyroptotic features include ion influx, cell swelling, membrane pore formation, mitochondrial depolarization, chromatin condensation and membrane rupture, resulting in cytoplasmic secretion of interleukin (IL)-1β, IL-18 and other contents, thereby triggering inflammation [61].”
BackgroundVernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074 · cited 6×
“Sci. 2022, 23, 2668. https://doi.org/10.3390/ijms23052668 https://www.mdpi.com/journal/ijms HCC in the context of NAFLD can occur even in the absence of cirrhosis [7].”
BackgroundInfluentialAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · cited 1×
“For instance, macrophages were identified as key drivers in the regulation of inflammationassociated insulin signaling [20,21].”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 1×
“In this context, combinatorial therapeutic strategies targeting multiple pathways in parallel appear attractive and potentially bear significant advantages over single drug treatments (Figure 2) [210,211].”
Background
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationKamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 81
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 80
NAFLD and HBV interplay - related mechanisms underlying liver disease progression
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M., & Triantos, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965548 · Cited by 70
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 67
“In lipid metabolism, PPARα decreases liver fat synthesis through fatty acid transport, apolipoproteins production, genes expressed in β -oxidation [51, 68] or indirectly harmonizing via the LXR signaling pathway[68, 69] .”
BackgroundTreating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 56
Self-citationPuengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126696 · Cited by 59
“Over the last years, translational and clinical studies have identified many potential drug targets including metabolic, inflammatory and cell death pathways [2,8,9].”
BackgroundSelf-citationMASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 59
Macrophage Signaling Pathways in Health and Disease: From Bench to Bedside Applications
Chi, Y., Jiang, H., Yin, Y., Zhou, X., Shao, Y., Li, Y., & Rao, J. (2025) · MedComm · doi:10.1002/mco2.70256 · Cited by 62
“Data from mechanistic studies implicate macrophage-mediated processes in its anti-MASH activity [275].”
He, X., Ma, J., Xue, Y., Yang, X., Wang, P., Zhang, L., Li, N., & Shi, Z. (2024) · Current Genomics · doi:10.2174/0113892029313473240919105819 · Cited by 54
Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Pan, J., Zhou, W., Xu, R., Xing, L., Ji, G., & Dang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113127 · Cited by 52
Zhao, Z., Deng, Z., Huang, S., Ning, M., Feng, Y., Shen, Y., Zhao, Q., & Leng, Y. (2022) · Nutrients · doi:10.3390/nu14122411 · Cited by 45
“Mounting evidence has revealed the critical role of nuclear receptors in the pathogenesis and treatment of NAFLD [39].”
BackgroundThyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
“to activate genes in lipid and bile acid metabolism through its nuclear receptor function [113].”
BackgroundSelf-citationLi, D., Ma, J.-M., Li, M., Gao, L., Fan, Y., Zhang, Y., Tao, X., & Yang, J. (2022) · Nutrients · doi:10.3390/nu14153247 · Cited by 47
“One of the isoforms is PPARα, which is mainly expressed in fatty tissues [22].”
BackgroundProgrammed cell death and lipid metabolism of macrophages in NAFLD
Xiao, Z., Liu, M., Yang, F., Liu, G., Liu, J., Zhao, W., Ma, S., & Duan, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118449 · Cited by 42
“Thus, metabolic regulation may be central to the functional plasticity of macrophages, and FAO plays an essential role in inflammatory and metabolism-mediated phenotypic changes in immune cells.”
BackgroundInfluentialThe role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies
Ma, X., Qiu, J., Zou, S., Tan, L., & Miao, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494250 · Cited by 35
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“FXR is the key nuclear receptor involved in bile acid metabolism and is key regulator of various metabolic processes such as hepatic glycogenolysis, gluconeogenesis, or fatty acid oxidation in a wide range of tissues [32].”
InfluentialSelf-citationFibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
Subramanian, P., Hampe, J., Tacke, F., & Chavakis, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136996 · Cited by 37
“Currently, obeticholic acid, a FXR agonist; PPAR agonist namely, Lanifibranor; glucagon-like peptide 1 receptor (GLP1R) agonist Semaglutide, thyroid hormone receptor β (THRβ) agonist Resmetirom and stearoyl-CoA desaturase 1 (SCD1) inhibitor Aramchol are in clinical trials for MAFLD treatment [143,144].”
BackgroundSelf-citationXiao, J., Xiang, H., Xiang, H., Sun, Z., Xu, J., Ren, H., Hu, P., & Peng, M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176113 · Cited by 33
Albadawy, R. M., Hasanin, A. H., Agwa, S. H. A., Hamady, S., Aboul-Ela, Y. M., Raafat, M. H., Kamar, S. S., Othman, M. O., Yahia, Y. A., & Matboli, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710148 · Cited by 31
“Despite the noticeable prevalence of nonalcoholic steatohepatitis (NASH) and its risk of progression to cirrhosis and hepatocellular carcinoma (HCC), approved pharmacological compounds for NASH are still lacking [20].”
BackgroundKohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
“(Canton et al., 2013; Puengel et al., 2022a) Furthermore, Cd36 targeted silencing in KCs but not in MoMFs led to decreased liver oxidative stress (reduced malondialdehyde and reactive oxygen species accumulation) although this did not affect liver total triglyceride levels in obese mice.”
BackgroundSelf-citationAntwi, M. B., Jennings, A., Lefere, S., Clarisse, D., Geerts, A. M., Devisscher, L., & Bosscher, K. D. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00013-6 · Cited by 27
Nikolaou, E. M., Kalafati, I. P., & Dedoussis, G. V. (2024) · Nutrients · doi:10.3390/nu16081124 · Cited by 24
“…lipid metabolism in the liver (Figure 1), the pregnane X receptor (PXR), the liver X receptor (LXR), and the aryl hydrocarbon receptor (AhR) promote lipogenesis, whereas proliferator-activated receptors (PPARs) and thyroid receptors inhibit hepatic steatosis and promote VLDL secretion [4,32].”
BackgroundDual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease
Xu, Y., An, Z., Wang, S., Ni, Y., Zhou, M., Feng, Q., Gou, X., Xu, M., & Qi, Y. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429259143230927110556 · Cited by 35
Tsomidis, I., Tsakou, A., Voumvouraki, A., & Kouroumalis, E. (2026) · Biomedicines · doi:10.3390/biomedicines14010151 · Cited by 25
Kim, W., Li, M., Jin, H., Yang, H., Türkez, H., Uhlén, M., Zhang, C., & Mardinoğlu, A. (2023) · iScience · doi:10.1016/j.isci.2023.107727 · Cited by 28
RXRα modulates hepatic stellate cell activation and liver fibrosis by targeting CaMKKβ–AMPKα axis
Cai, L., Yin, M., Peng, S., Fen, L., Lai, L., Zhang, X., Xie, L., Wang, C., Zhou, H., Zhan, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.023 · Cited by 22
“…retinoid X receptor-alpha (RXR a ), liver X receptor (LXR), farnesoid X receptor (FXR), peroxisome proliferator-activated receptors (PPARs), and thyroid hormone receptor (T 3 R) are highly expressed in the liver and play crucial roles in regulating bile acid, lipid, and glucose homeostasis 4 .”
Research Progress on the Mechanism of Acupuncture Treatment for Nonalcoholic Fatty Liver Disease
Li, B., & Li, F. (2022) · Gastroenterology Research and Practice · doi:10.1155/2022/5259088 · Cited by 23
“The clinical characteristics of NAFLD mainly consist of abnormal fatty deposition of hepatocytes, hepatic steatosis, severe damage with a characteristic histological appearance, hepatomegaly, and hepatic inflammatory reaction [3, 4].”
BackgroundTargeting nuclear receptors for NASH/MASH: From bench to bedside
Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 23
Elshinshawy, S., Haddad, H. E. E., Alem, S. A., Shaker, O. G., Salam, R., Yosry, A., & Elebrashy, I. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.03.004 · Cited by 19
Yan, Y., Yuan, H., Yang, F., Na, H., Yu, X., Liu, J. R., & Wang, Y. (2024) · AMB Express · doi:10.1186/s13568-024-01756-7 · Cited by 18
“It has been reported that PPARγ expression is significantly increased in the NAFLD models (Puengel et al. 2022).”
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension
Petrenko, O., Königshofer, P., Brusilovskaya, K., Hofer, B., Bareiner, K., Simbrunner, B., Jühling, F., Baumert, T. F., Lupberger, J., Trauner, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109301 · Cited by 20
Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease
Dubois, V., Lefèbvre, P., Staels, B., & Eeckhoute, J. (2024) · Gut · doi:10.1136/gutjnl-2023-331741 · Cited by 18
“38 41 Of note, expanding our understanding of NR functions in the liver beyond hepatocytes has notably been enabled by technological breakthroughs, especially those related to purification of individual liver cell types and/or single-cell/nuclei resolution analyses of gene expression, which allowed…”
Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease
Patil, N. Y., Friedman, J. E., & Joshi, A. (2023) · Receptors · doi:10.3390/receptors2010001 · Cited by 19
“Despite multiple previous reviews interrogating the role of nuclear receptors in NAFLD, a comprehensive report illustrating involvement and effect of AhR signaling in NAFLD pathophysiology is absent [13,14].”
BackgroundExploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs
Mukherjee, A. G., Wanjari, U. R., Gopalakrishnan, A. V., Katturajan, R., Kannampuzha, S., Murali, R., Namachivayam, A., Ganesan, R., Renu, K., Dey, A., et al. (2022) · Cells · doi:10.3390/cells11243959 · Cited by 17
“The nuclear receptor superfamily, of which PPARs are a part, has been shown to govern distinct stages of NAFLD through its many subtypes, making it an appealing target for therapeutic intervention [24].”
BackgroundLigand-induced shifts in conformational ensembles that describe transcriptional activation
Khan, S. H., Braet, S. M., Koehler, S. J., Elacqua, E., Anand, G. S., & Okafor, C. D. (2022) · eLife · doi:10.7554/elife.80140 · Cited by 16
“Nuclear receptors (NRs) are master regulators of diverse physiological functions, including reproduction, inflammation, development, and metabolism (Francis et al., 2003; Lee et al., 2008; Rhen and Cidlowski, 2005; Puengel et al., 2022; Sun et al., 2021; Connelly et al., 2022; Tenbaum and Baniahmad, 1997).”
BackgroundReviewing the function of macrophages in liver disease
Chen, L., Guillot, A., & Tacke, F. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2508963 · Cited by 16
“Drugs targeting nuclear receptors like FXR, LXR, and PPARs – which influence macrophage metabolism – have also been explored, but none have proven sufficiently effective or safe in phase 3 trials for the treatment of MASH and liver fibrosis [164].”
Self-citationSun, Q., Guo, Y., Hu, W., Zhang, M., Wang, S., Lei, Y., Meng, H., Li, N., Xu, P., Li, Z., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001449 · Cited by 14
“Hepatic nuclear receptors (NRs) are upstream transcriptional regulators that play important roles in the pathophysiology of NAFLD by controlling various metabolic processes (Moreau et al., 2008; Cariello et al., 2021; Puengel et al., 2022).”
BackgroundLiver Macrophage Diversity in Health and Disease
Horn, P., & Tacke, F. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-65944-7_7 · Cited by 17
Self-citationNovel regulators of hepatic macrophages in liver fibrosis
Tang, X., Bai, M., Du, X., Wang, H., Liu, M., Fu, X., Zhang, H., Liang, S., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705503 · Cited by 12
Hermanson, J. B., Tolba, S. A., Chrisler, E. A., & Leone, V. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109704 · Cited by 14
Transcriptomics of natural and synthetic vitamin D in human hepatocyte lipotoxicity
Bartolini, D., Zatini, L., Migni, A., Frammartino, T., Guerrini, A., Garetto, S., Lucci, J., Moscardini, I. F., Marcantonini, G., Stabile, A. M., et al. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109319 · Cited by 12
Karri, K., & Waxman, D. J. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116550 · Cited by 14
Niu, W., Feng, Y., Peng, M., & Jinyan, C. (2024) · Phytotherapy Research · doi:10.1002/ptr.8276 · Cited by 11
“Peroxisome proliferator-activated receptors (PPAR) belong to the nuclear receptor superfamily and can be activated by dietary fatty acids and related metabolic derivatives, regulating lipid and glucose metabolism (Puengel et al., 2022).”
Wang, T., Xiao, Y., Hu, Z., Gu, J., Hua, R., Hai, Z., Chen, X., Zhang, J. V., Yu, Z., Wu, T., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.862506 · Cited by 13
“PPARs have previously been reported to coordinate lipid and glucose metabolism, and the abnormal expression of PPARs might lead to a perturbation of lipid metabolism, which is characteristic of various metabolic syndromes (Alatshan and Benkő 2021; Puengel et al., 2022).”
BackgroundLee, M.-S., Felipe‐Dimog, E. B., Yang, J., Chen, Y.-Y., Wu, K., Kuo, H.-J., Lin, T.-C., Wang, C.-L., Hsieh, M., Lin, C.-Y., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092518 · Cited by 11
PPARs as Key Transcription Regulators at the Crossroads of Metabolism and Inflammation
Vázquez‐Carrera, M., & Wahli, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084467 · Cited by 10
TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases
Kim, J. E., Kim, E.-M., & Lee, S. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158387 · Cited by 9
“Chronic injury to hepatocytes results in steatosis, inflammation and steatohepatitis, and fibrosis [78].”
BackgroundMarroncini, G., Anceschi, C., Naldi, L., Fibbi, B., Brogi, M., Lanzilao, L., Fanelli, A., Maggi, M., & Peri, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01962-9 · Cited by 9
“, α, γ, ẟ) have been associated to the pathogenesis of liver steatosis in humans [32].”
BackgroundChen, S., Zeng, Q., Cai, X., Xue, J., Yin, G., Song, P., Tang, L., Klein, C., Tacke, F., Guillot, A., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.98362 · Cited by 8
Self-citationChen, S., Tang, L., Guillot, A., & Liu, H. (2022) · Metabolites · doi:10.3390/metabo13010011 · Cited by 10
“Commonly caused by constant obesity, NASH is a complex of fat deposition, fatty acid metabolism, and inflammatory modulation [31,32].”
BackgroundSelf-citationWang, W., Li, L., Li, X., Chen, J., Wang, R., Yang, Q., Wang, C., & Meng, Q. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117308 · Cited by 9
Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development
Jin, Y., & Heo, K. (2023) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.4.299 · Cited by 11
“Activated inf lammatory signaling pathway promotes the IR signaling pathway and fibrogenesis, consequently activating the transition from NAFL to NASH [12].”
BackgroundLabes, S., Froy, O., Tabach, Y., Shamir, R., Shouval, D. S., & Weintraub, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031488 · Cited by 8
“It has been shown that the activation of PPARs, ROR γ and PGC1 α exerts anti-inflammatory properties, mainly by suppressing the expression of pro-inflammatory genes, such as IL-17, IL-1 β and TNF α [19,20,37].”
BackgroundDijck, E. V., Laere, S. V., Logie, E., Timmermans, S., Fransén, E., Ibrahim, J., Kendall, T. J., Fallowfield, J. A., Mateiu, L. M., Libert, C., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01945-6 · Cited by 13
“NRs have been elabo-rately explored in MASLD, as they play important roles in lipid metabolism, inflammation, and fibrosis [99–101, 131, 132].”
PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100590 · Cited by 7
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy
Wang, Y., Yang, L., Xu, Q., Liu, T., He, H., Liu, L., & Yin, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010032 · Cited by 5
“Both preclinical and clinical studies have shown that OCA treatment effectively inhibited HSC activation and prevented liver fibrosis [7–9].”
β-sitosterol protects against ANIT-induced hepatotoxicity and cholestasis via FXR activation
Yan, Y., Wang, W., Yan, A., Zhu, H., & Meng, Q. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106020 · Cited by 5
Chen, C., Gong, J., Li, M., Pan, S., Xia, G., Xu, Y., Li, H., & Lin, Q. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104224 · Cited by 5
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 6
Liu, D., Luo, R., Zhou, Q., & Li, M. (2024) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2024053012 · Cited by 5
Cheng, X., Baki, V. B., Moran, M., Liu, B., Yu, J., Zhao, M., Li, Q., Riethoven, J.-J. M., Gurumurth, C. B., Harris, E. N., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101977 · Cited by 5
“Nuclear receptors have various functions regulating metabolism, immunity, and in fl ammation [34,76].”
Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology
Cheon, I., Kim, M., Kim, K. H., & Ko, S. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.07.023 · Cited by 7
“30 e 32 Importantly, diverse NR regulators are currently approved for clinical trials in several hepatic disorders related to CCA, such as liver cirrhosis 33 e 35 and cholestasis.”
CXCL6 promotes the progression of NAFLD through regulation of PPARα
Zou, Y., Zhan, T., Liu, J., Tan, J., Liu, W., Huang, S., cai, Y., Huang, X., Huang, X., & Xia, T. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156459 · Cited by 6
Frankovic, I., Djuricic, I. D., Ninić, A., Vekić, J., Vorkapic, T., Erceg, S., Gojković, T., Tomašević, R., Mamić, M., Mitrović, M., et al. (2024) · Biomolecules · doi:10.3390/biom14080902 · Cited by 4
“Novel research repeatedly points towards common molecular mechanisms, which bring together these different pathways and shed light on the role of peroxisome proliferator-activated receptors (PPARs) in counteracting these processes [21,22].”
BackgroundHernández, A. F., González-Rinne, A. M., Hernández‐Bustabad, A., Guerra-Rodríguez, R., Saiz-Udaeta, A. P., Alonso-Titos, J., Marrero, D., Rivero-González, A., Quintana, C. A. S., Esteban, P. R., et al. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000543276 · Cited by 4
Yehezkel, A. S., Abudi, N., Nevo, Y., Benyamini, H., Elgavish, S., Weinstock, M., & Abramovitch, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226808 · Cited by 4
“Frontiers in Endocrinology 09 Numerous nuclear receptors including FXR, LXR, RXR, and AhR have been suggested as regulators of NAFLD and NASH progression (27, 28).”
BackgroundStan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2628 · Cited by 4
“Taking into account this function of NRs, their pharmacological targeting could positively influence the evolution of NASH by modulating one or more pathways of disease progression, especially by reducing the metabolic stress at the level of hepatocytes [61].”
BackgroundCong, S., Wang, S., Qiao, Y., Gu, S., Susu, L., Chai, X., & Yongsheng, Z. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.460 · Cited by 4
“Nuclear receptors act as mediators linking the metabolic, inflammatory and fibrotic processes in NAFLD 35 After analysing the top 10 articles with the highest number of citations in our research we found that the top 3 of them all described research related to the FXR signalling pathway.”
BackgroundSrikanth, P., Shaik, K. M., Patibandla, V., Kumar, D., & Nandi, S. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101425 · Cited by 3
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Self-citationKatsuyama, H., Horinaka, S., Hakoshima, M., Adachi, H., & Yanai, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164929 · Cited by 3
“They function as nuclear receptors with crucial roles in lipid metabolism [14–16].”
BackgroundHui, Y., Qu, J., Yang, J., Zhang, H., Chen, L., Miao, N., Zhang, Q., Xu, H., Li, Y., & Li, Q. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70142 · Cited by 2
Liu, L., Duan, X., & Ju, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1744299 · Cited by 3
The C-reactive Protein–Triglyceride–Glucose Index in Relation to Liver Disease
Fang, J., & Liu, L. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261433444 · Cited by 2
“9-11 These factors collectively promote abnormal hepatic fat accumulation and activate inflammatory responses, 12 which in turn drive hepatic steatosis and fibrosis.”
Kim, K. B., Baek, S., Ko, S., Moon, S., Lee, K. P., & Ahn, S. H. (2023) · Physical Activity and Nutrition · doi:10.20463/pan.2023.0039 · Cited by 1
Topchieva, L. V., Валерьевна, К. И., Дуданова, О. П., Vasilyeva, A. V., & Жулай, Г. А. (2024) · Biology Bulletin · doi:10.1134/s1062359024607742 · Cited by 1
“Activation of PPAR β / δ plays a role in hepatoprotection through a number of mechanisms, such as through inhibition of SREBP1c, regulation of low-density lipoprotein receptors (Puengel et al., 2022).”
InfluentialYin, L.-Y., Li, J., Tai, X., Zhang, G., Luan, M., Zhong, B., & Li, F. (2025) · Food & Nutrition Research · doi:10.29219/fnr.v69.11634 · Cited by 1
“SREBP-1c is an important regulatory gene for lipogenesis as its activation increases FAS expression, resulting in lipid accumulation (38, 39).”
Kimura, T., Hino, K., Kuroida, M., & Udagawa, J. (2025) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s204017442510024x · Cited by 1
“…and modulates lipid storage in the liver, 14,17 (iii) RXRs heterodimerizes with PPARs and plays a role in regulating hepatic steatosis progression, 18 (iv) retinoic acid is a key regulator of lipid metabolism in the liver, 19 and RAR α plays an important role in preventing hepatic steatosis, 20…”
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
High altitude adaptation: role of nuclear receptor’s exosomes
Huirem, R. S., & Reddy, M. K. P. (2026) · International Journal of Biometeorology · doi:10.1007/s00484-026-03188-3 · Cited by 1
“NRs have been associated with a number of illnesses (Luan et al. 2022, Xu 2023, Yang et al. 2024), including cancer (Puengel et al. 2022, Zhao et al. 2020, Dhiman et al. 2018, Sun et al. 2021), and can serve as markers for a variety of physiological and pathological responses.”
MHY5456, an FXR Agonist, Ameliorates Hepatic Steatosis and Fibrosis in a Mouse Model of MASLD
Kim, M.-J., Kang, H., Yoo, J., Ha, S., Kim, J., Kim, B. M., Park, D. E., Chung, H. Y., Kim, D., Moon, H. R., et al. (2026) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.256 · Cited by 1
Liang, H., Xie, Y. D., Dai, Y., Yang, X., Zheng, X., Yang, J., Liu, Y., Wu, C., Chen, S. Y., Zhang, M., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03424-25 · Cited by 2
Liu, Y., Hu, Y., & Shan, Z. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i5.344 · Cited by 1
Mantovani, A., & Dalbeni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087241 · Cited by 1
“The other narrative reviews published in our Special Issue discussed other relevant issues about NAFLD/MAFLD, including the role of fibroblast growth factors [15], hydrogen sulfide [16], nuclear receptors [17],”
BackgroundImpact de perturbateurs endocriniens sur la stéatose hépatique et sa progression pathologique
Mentec, H. L. (2023) · theses.fr (ABES) · doi:10.70675/ecaf4c85z1295z4280zb43ezdb58695f5ff8
Role of Kupffer cells and other immune cells
Puengel, T., & Tacke, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00024-3
Self-citationPharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Topchieva, L., Жулай, Г. А., Валерьевна, К. И., Дуданова, О. П., & Vasilyeva, A. V. (2024) · Известия Российской академии наук Серия биологическая · doi:10.31857/s1026347024050023
Puengel, T. (2023) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-39885
Self-citationCash, S. B., Saikali, M. F., Magomedova, L., Shawky, S. A., Molaei, F., Shi, J., Thibeault, P. E., Lyons, S. A., Kwok, C., Kiyota, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.03.703579
Fatty Acid Oxidation Suppression Reprograms Fibroblasts in Fibrostenotic Crohn’s DiseasePreprint
Aljabban, J. J., Awad, A., McMichael, B. D., Gartner, V., Thomas, V., Huan, B., Weaver, D., Lian, G., Beasley, C., Lau, G. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.723289
“…increased expression of glycolytic regulators ( HK1, HK2, PFKFB3, PDK1 ) (6, 10), reduced expression of PPARγ and its downstream targets ( PLIN2, FABP4 )(31, 32), and skewing of the TGF-β pathway with decreased SMAD7 , ID1 , and ID3 alongside increased THBS1 , SNAI1 , NOX4 , and MMP2 (33–38) .”
Liu, M., Huang, R., Wang, S., Lin, Y., Xiong, T., Li, R., Zheng, W., Huang, Q., Nan, Y., Liu, Z., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71320
Cui, L., He, S., Song, W., Jiang, B., Yuan, C., Guo, L., Liu, K., Dong, J., Li, J., & Wang, H. (2026) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2026.105666
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177805
“…by bile acids, FXR suppresses hepatic de novo lipogenesis, promotes fatty acid β -oxidation, and limits bile acid synthesis by inducing the small heterodimer partner (SHP), which inhibits cholesterol 7 α -hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid biosynthesis [18,19,42].”
InfluentialLiu, H., Zhang, M., & Tacke, F. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s543657
Self-citationExploring the Expanding Role of Nuclear Receptor LRH‐1/NR5A2 in Cell Biology and Immunity
Tsapalou, E., Michael, P., Georgoula, M., Michail, K., Papoutsopoulou, S., & Campbell, B. J. (2026) · International Journal of Cell Biology · doi:10.1155/ijcb/3335387
Metadata
- Authors
- Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Tacke, Frank
- Peiseler, Moritz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2668
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910763
- OpenAlex
- W4214523533
- Cited by
- 95
- References
- 238
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 30 · 2023: 22 · 2022: 18
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft (SFB/TRR296, CRC1382)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (CSP 21-1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, nuclear receptors, peroxisome proliferator-activated receptors, liver inflammation, liver fibrosis, metabolic syndrome, insulin resistance, immunometabolism, hepatocyte death, lipotoxicity, gut dysbiosis, hepatic macrophages, hepatocellular carcinoma, combination therapy
- MeSH terms
- Diabetes Mellitus, Type 2, Fibrosis, Carcinoma, Hepatocellular, Humans, Inflammation, Liver, Liver Neoplasms, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.